Method for detecting single nucleotide variation in tumor and plasma samples

By combining the amplification block mutation system and digital droplet technology, the digital PCR method of amplification droplets is solved, and the existing SNV detection technology is achieved with high SNV in tumor and plasma samples. Sensitivity and specificity detection, suitable for clinical practice.

CN118995892APending Publication Date: 2024-11-22MEI HOSPITAL UNIV OF CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410904190.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-28
Filing Date
2024-07-08
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing single nucleotide variant (SNV) detection technology has problems such as low sensitivity, high cost and high application complexity, and it is difficult to meet the general and high specificity detection needs.

Method used

Using the mutant selective amplified droplet digital PCR (MSA-ddPCR) method, the amplification block mutation system is combined with digital droplet technology, and the tumor is achieved by designing specific primers and probes, using fluorescence detection and Poisson distribution analysis. and high sensitivity and specific detection of SNV in plasma samples.

Benefits of technology

It realizes fast and accurate detection of SNV, which can be easily applied in clinical practice, with high specificity, strong sensitivity, fast speed and low cost, and even better than some high-throughput sequencing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995892A_ABST
    Figure CN118995892A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting single nucleotide variation in tumor and plasma samples, and relates to the field of biological detection.The method comprises the following steps that 1, samples are prepared; 2, preparing a mixture; step 3, micro-droplet generation; step 4, carrying out completely independent PCR (Polymerase Chain Reaction) amplification reaction on each microdroplet; step 5, fluorescence detection; step 6, data analysis; the MSA-ddPCR method disclosed by the invention is high in specificity, strong in sensitivity, accurate in result and rapid, and can be easily applied to clinical practice.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection, and in particular to a method for detecting single nucleotide variations in tumor and plasma samples. Background Art

[0002] Precision medicine focuses on the individual characteristics of each patient and aims to provide patients with more accurate treatment and prevention strategies. Some studies have shown that routine testing of mutant genes with established clinical relevance can be used for early screening and diagnosis of the disease, as well as for evaluating treatment response and monitoring recurrence. Single nucleotide variants (SNVs) are a common form of gene mutation. For cancer, certain specific SNVs may lead to the occurrence and development of cancer. Therefore, by detecting SNVs, we can understand the individual's cancer risk, conduct early screening, and even provide personalized treatment plans. For example, certain SNVs of the BRCA1 and BRCA2 genes are considered to be important risk factors for breast cancer and ovarian cancer. Similarly, the TP53R249S SNV mutation is a common mutation site for HCC in Southeast Asian populations. It can be used as a biomarker for early detection and provide potential opportunities for targeted intervention.

[0003] Currently, widely used SNVs detection technologies include next-generation sequencing (NGS), TaqMan-MGB qPCR, and amplification-retarded mutation system qPCR (ARMS-qPCR). NGS, also known as high-throughput sequencing, is the gold standard method for detecting SNVs in clinical practice. However, it requires professional operation and complex equipment. In addition, the specificity of NGS test results is also controversial (studies have reported that its error rate is 0.1%-15%). TaqMan-MGB qPCR and ARMS-qPCR have similar principles and specificity, and both rely on probes or primers that do not match the target gene to detect SNVs. Both methods are effective methods for detecting mutant genes. However, since the mutant genes and wild-type genes of TaqMan-MGB qPCR and ARMS-qPCR are determined by calculating ΔCt values ​​or using electrophoresis, the accuracy of these two methods will be affected to a certain extent (sensitivity ≥ 1%). In short, the above technologies all face limitations in practical application: such as low mutation copy number in samples, sensitivity issues, and high cost. Currently, there is still an unmet need for generally applicable and highly specific SNVs detection methods.

[0004] In order to meet the demand for a generally applicable and highly specific SNVs detection method, the present invention designed a new method combining an amplification-blocking mutation system with digital droplet technology, named mutation-selected amplification droplet digital PCR (MSA-ddPCR), which is used to detect gene mutations in clinical samples. Summary of the invention

[0005] In order to address the deficiencies of the prior art, the object of the present invention is to provide a method for detecting single nucleotide variations in tumor and plasma samples. The MSA-ddPCR method of the present invention has high specificity, strong sensitivity, accurate results, and is rapid, and can be easily applied in clinical practice.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] A method for detecting single nucleotide variants in tumor and plasma samples, comprising the following steps:

[0008] Step 1, sample preparation;

[0009] Step 2, mixture preparation;

[0010] Step 3, droplet generation;

[0011] Step 4: A completely independent PCR amplification reaction is performed on each droplet, wherein the PCR amplification reaction adopts a mutation selection amplification droplet digital PCR method that combines an amplification blocking mutation system with a digital droplet nucleic acid amplification technology;

[0012] Step 5: Fluorescence detection:

[0013] Extension phase: The long wild-type primer can bind to all DNA containing the TP53WT site and successfully extend. When the long mutant primer binds to the TP53WT template, the extension reaction is blocked due to the base mismatch at the 3' end of the long mutant primer. On the contrary, when the long mutant primer binds to the mutant template, it will successfully extend forward in the extension phase. The double-stranded DNA containing the extra fragment at the 5' end of the long mutant primer can interact with the primer and probe, and then emit a corresponding fluorescent signal.

[0014] Fluorescence detection stage: by combining with mutant probes or wild-type probes, the fluorescence signal of double-stranded DNA generated during primer binding can be detected; the droplets containing wild-type DNA can detect fluorescence signals in the VIC channel, the droplets containing mutant DNA can detect fluorescence signals in the FAM channel, and the droplets without target DNA molecules are negative droplets. The analysis instrument automatically collects the fluorescence signals emitted from different channels in all droplets and divides them into different clusters;

[0015] Step 6, data analysis: Calculate the copy number of wild-type genes and mutant genes in each sample based on Poisson distribution, determine the frequency of variant alleles, and finally generate a clinical test report.

[0016] In the aforementioned method for detecting single nucleotide variants in tumor and plasma samples, the mutation selection amplification droplet digital PCR method in step 4 comprises the following steps:

[0017] Step a, design primers and probes:

[0018] The primers include: a long primer for identifying mutant and wild-type fragments, and a short primer involved in subsequent extension and fluorescence detection; the long primers are L-Primer M1 and L-Primer W1, and the short primers are Primer 2, Primer 3, and Primer 4;

[0019] The probe is a probe with MGB, and the minor groove binder MGB at the 3' end of the probe can match the minor groove of the DNA helix;

[0020] Optimize the position and type of mismatched bases: select the second to last base at the 3' end and design an AG base mismatch;

[0021] Step b, combined with digital droplet generation technology: this technology can reduce the number of DNA molecules in each reaction microchamber to ≤1; the primer probe and sample are amplified in the MSA-ddPCR amplification system.

[0022] In the aforementioned method for detecting single nucleotide variants in tumor and plasma samples, the mutation selection amplification droplet digital PCR method in step 4 comprises the following steps:

[0023] Step a, design primers and probes:

[0024] The primers include: a long primer for identifying mutant and wild-type fragments, and a short primer involved in subsequent extension and fluorescence detection; the long primers are L-Primer M1 and L-Primer W1, and the short primers are Primer 2, Primer 3, and Primer 4;

[0025] The probe is a probe with MGB, and the small groove adhesive MGB at the 3' end of the probe can match the small groove of the DNA helix; optimize the position and type of unpaired bases: select the second to last base at the 3' end, and design the AG base mismatch;

[0026] The sequence of L-Primer W1 is:

[0027] 5'GACGCCAGAATTGTCCGGTCGACGTCACGCCTGGCCCCAGCTGCTCACCATCG CT 3'SEQ IDNo: 01;

[0028] The sequence of L-Primer M1 is:

[0029] 5'GACGCCAGAATTGTCCGGTTGCCGACAGCCTGGCAGATGATGGTGAGGATGGG AC 3'SEQ IDNo: 02;

[0030] The sequence of Primer 2 is: 5'GACGCCAGAATTGTCCGGT 3'SEQ ID No: 03;

[0031] The sequence of Primer 3 is: 5'CTTGCCACAGGTCTCCCCAA 3' SEQ ID No: 04;

[0032] The sequence of Primer 4 is: 5'TGGCCATCTACAAGCAGTCA 3' SEQ ID No: 05;

[0033] The sequence of the Wild Probe is: 5'VIC-CGACGTCACGCCTGGC-MGB 3' SEQ ID No: 06;

[0034] The sequence of Mutant Probe is: 5'6-FAM-TGCCGACAGCCTGGCA-MGB 3'SEQ ID No: 07.

[0035] In the aforementioned method for detecting single nucleotide variations in tumor and plasma samples, in step b, the nucleic acid amplification improver is betaine.

[0036] In the aforementioned method for detecting single nucleotide variations in tumor and plasma samples, in step b, the optimal concentration of the long primer is 1 / 10 of that of the short primer.

[0037] In the aforementioned method for detecting single nucleotide variants in tumor and plasma samples, the reaction system of the MSA-ddPCR amplification system in step b includes: the total volume of the MSA-ddPCR is 14 μL, including 7 μL of Premix ExTaq TM(Probe qPCR), 0.7μL L-Primer-W1 (1μM), 0.7μL L-Primer-M1 (1μM), 0.7μL Primer2 (10μM), 0.7μL Primer 3 (10μM), 0.7μL Primer 4 (10μM), 0.7μL Wild Probe (10μM), 0.7μL Mutant Probe (10μM), 1.4μL template DNA and 0.7μL DEPC H2O;

[0038] In the aforementioned method for detecting single nucleotide variations in tumor and plasma samples, the amplification steps of the MSA-ddPCR amplification system in step b are as follows: 95°C for 30 seconds (pre-denaturation), followed by 37 cycles of 95°C for 5 seconds (denaturation), 68°C for 30 seconds (annealing and extension), and then cooling to 50°C for 15 seconds.

[0039] The aforementioned method for detecting single nucleotide variants in tumor and plasma samples, the detection sample includes: free cell DNA in plasma samples or FFPE tissue samples. The benefits of the present invention are:

[0040] Compared with other existing SNVs detection methods, the method of the present invention has a significant improvement in the LOD of mutation detection;

[0041] In the application of clinical samples, the ability of MSA-ddPCR to detect mutant DNA is similar to or even better than that of amplicon high-throughput sequencing methods, which means that MSA-ddPCR can detect lower copy numbers in clinical samples;

[0042] MSA-ddPCR can not only calculate the absolute copy number of wild-type DNA and mutant DNA in one reaction, but also is faster and less expensive (4 hours, $30 per time) compared to high-throughput sequencing (7 days, $100 per time).

[0043] Currently, most available mutation detection protocols focus on their capabilities in plasma samples. In addition to detecting plasma samples, the method of the present invention can also be used for low-quality DNA extracted from FFPE tissues. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 It is a schematic diagram of the detection method of the present invention ((A) Flow chart of MSA-ddPCR mutation detection in clinical samples; (B) Detailed mutation selection extension process);

[0045] Figure 2Schematic diagram of the fluorescence detection process of the present invention ((A) Schematic diagram of MSA-ddPCR for mutant gene and wild-type gene detection; (B) Representative analysis results of FAM channel MSA-ddPCR; (C) Two-dimensional analysis results of droplet digital PCR; (D) Representative chip photos);

[0046] Figure 3 It is the optimization experiment and sensitivity evaluation of the present invention ((A) Analysis results of MSA-ddPCR at different annealing temperatures in FAM and VIC channels: the upper points represent positive droplets, and the lower points represent negative droplets; (B) Comparison of the optimization effects of betaine and DMSO: TP53R249S and TP53WT (TP53wild-type) plasmid DNA are used as templates for MSA-ddPCR; (C) Analysis results of plasmid DNA for different VAFs in FAM and VIC channels: the concentration of TP53WT plasmid DNA is constant; (D) MSA-ddPCR results of 20 blank samples: LOB: limit of blank; (E) Sensitivity and regression analysis of MSA-ddPCR);

[0047] Figure 4 It is a result diagram of mutations in clinical samples of the present invention ((A) Summary of detection results of MSA-ddPCR and amplicon high-throughput sequencing in plasma samples and FFPE (formalin-fixed paraffin-embedded) tissue samples; VAF: variant allele frequency; (B) Summary table of negative-positive results; (C) Correlation analysis of detection results of MSA-ddPCR and amplicon high-throughput sequencing in 35 samples; ICC=0.743, 95%CI[0.548-0.862]; ICC: intraclass correlation coefficient, 95%CI: 95% confidence interval; (D) ROC curve; when amplicon high-throughput sequencing was used as a reference, the AUC was 0.941. ROC curve: receiver operating characteristic curve, AUC: area under the curve; (E) Comparison of VAFs in FFPE tissue samples and plasma samples). DETAILED DESCRIPTION

[0048] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0049] like Figure 1As shown, (A) Flowchart of MSA-ddPCR mutation detection in clinical samples. The workflow of MSA-ddPCR includes six steps: sample preparation, mixture preparation, droplet generation, amplification, fluorescence detection, and data analysis. In the amplification part, each droplet will perform a completely independent PCR amplification reaction, which physically minimizes other interfering substances that may exist in the reaction system. In the fluorescence detection part, droplets containing wild-type DNA can detect fluorescence signals in the VIC channel (gray); droplets containing mutant DNA can also detect fluorescence signals in the FAM channel (gray). Droplets without target DNA molecules are negative droplets because no corresponding fluorescence signals can be detected in either channel. The analysis instrument automatically collects the fluorescence signals emitted by different channels in all droplets and divides them into different clusters. Finally, the copy numbers of wild-type genes and mutant genes in each sample are calculated according to the Poisson distribution, and the variant allele frequency is determined, and finally a clinical test report is generated. 2D: two-dimensional. (B) Detailed mutation selection extension process. When the long mutant primer (L-Primer M1) binds to the TP53WT (TP53 wild-type) template, the extension reaction is blocked due to the base mismatch at the 3' end of the long primer. In contrast, when the long primer binds to the mutant template, it will successfully extend forward. (C) Schematic diagram of the detection gene site. The wild-type long primer pairing region should avoid frequent mutation sites and select conservative regions.

[0050] Example 1, MSA-ddPCR Experimental Design

[0051] The principle of MSA-ddPCR to detect mutant and wild-type genes is as follows Figure 2 As shown in A. In the primer binding part, long primers (L-Primer M1 and L-Primer W1) are used to identify mutant and wild-type fragments. The 5' ends of these primers are not paired with the target DNA fragment and will not affect the extension efficiency of the 3' end. On the contrary, only the 20bp fragment at the 3' end can bind to the target DNA (TableS1). The long wild-type primer (L-Primer W1) can bind to all DNA containing the TP53WT site and successfully extend. Similarly, the long mutant primer (L-Primer M1) can also bind to and extend templates containing mutation sites. However, it cannot bind to the TP53WT template ( Figure 1 B upper part). During the extension phase, the double-stranded DNA containing the extra fragment at the 5' end of the long primer can interact with the primer (Primer 2) and the probe (Mutant Probe or Wild Probe), and then emit corresponding fluorescent signals. Finally, the copy numbers of wild-type and mutant DNA can be calculated by the analysis software. The two-dimensional analysis results of droplet digital PCR are shown in Figure 2. Figure 2 C. The above amplification process occurs in the droplets generated in the droplet generation stage. Figure 2 D shows representative microarray images of fluorescent droplets and negative droplets. Fluorescent droplets containing TP53WT or TP53R249S DNA can detect fluorescent signals. Negative droplets without target DNA molecules cannot be detected.

[0052] like Figure 2 As shown, (A) Schematic diagram of MSA-ddPCR for mutant gene and wild-type gene detection. During the primer binding process, base mismatch at the 3' end of the long primer will greatly reduce the extension efficiency or even completely stop the extension. In the fluorescence detection stage, the fluorescence signal of the double-stranded DNA generated during the primer binding process can be detected by combining the mutant probe or the wild probe. (B) Representative analysis results of MSA-ddPCR in the FAM channel. Blue dots represent positive droplets in the FAM channel, and gray dots represent negative droplets. (C) Two-dimensional analysis results of droplet digital PCR. "Mutant" represents droplets containing mutant DNA, which can emit fluorescence signals in both the FAM and VIC channels; "Wild type + mutant" represents droplets containing wild-type DNA, which can only detect fluorescence signals in the VIC channel; "negative" represents droplets without any fluorescence signals detected. (D) Representative chip photos. Fluorescent droplets containing wild-type DNA or mutant DNA can detect fluorescence signals. Negative droplets cannot detect corresponding fluorescence signals in any channel.

[0053] The specific primer probe sequences are shown in Table 1:

[0054] Table 1 Primer probe sequences

[0055]

[0056] Note: The bold ones are optimized unpaired bases.

[0057] Example 3, optimization experiment:

[0058] The optimal amplification conditions play a key role in the detection accuracy of PCR-based methods. In order to improve the sensitivity and stability of MSA-ddPCR, we optimized and tested the annealing temperature and nucleic acid amplification modifiers. By comparing different annealing temperatures (65°C, 68°C, and 70°C), the ideal annealing temperature of MSA-ddPCR in the actual detection process can be determined. Figure 3As shown in A, when the annealing temperature is 68°C, the separation between the negative points (lower points) and the positive points (upper points) in the amplification image is the highest. Therefore, the annealing temperature of 68°C is considered to be the optimal temperature and was used in subsequent experiments. We then tested two nucleic acid amplification improvers, DMSO and betaine, to further improve the amplification efficiency. DMSO can improve the amplification efficiency by destroying the stability of double-stranded DNA by opening the secondary structure or weakening the hydrogen bonds between base pairs. Similarly, betaine can also significantly improve the yield and specificity of the PCR reaction. Figure 3 As shown in Figure B, the MSA-ddPCR detection performance using betaine was better. Therefore, we used betaine as a modifier in the following experiments. These optimized conditions ultimately enabled the established method to maintain the highest level of detection accuracy in subsequent experiments.

[0059] Specific MSA-ddPCR reaction system: The total volume of MSA-ddPCR is 14 μL, including 7 μL of PremixEx Taq TM (Probe qPCR), 0.7μL L-Primer-W1 (1μM), 0.7μL L-Primer-M1 (1μM), 0.7μL Primer 2 (10μM), 0.7μL Primer 3 (10μM), 0.7μL Primer 4 (10μM), 0.7μL Wild Probe (10μM), 0.7μL Mutant Probe (10μM), 1.4μL template DNA and 0.7μL DEPC H2O.

[0060] The specific MSA-PCR amplification steps were as follows: 95°C for 30 seconds (pre-denaturation), followed by 37 cycles of 95°C for 5 seconds (denaturation), 68°C for 30 seconds (annealing and extension), and then cooling to 50°C for 15 seconds.

[0061] Sensitivity assessment

[0062] In order to evaluate the sensitivity of the method, plasmid solutions with different VAFs (0.001%, 0.01%, 0.1%, 1%, 15%, 40%, 50%) were tested by MSA-ddPCR. The concentration of TP53WT plasmid DNA remained unchanged in the experiment. Figure 3 C lists the analysis results of MSA-ddPCR detection of plasmid DNA of different VAFs in FAM and VIC channels. The LoB is 0.449 copies / μL (FAM channel) and 0.452 copies / μL (VIC channel) ( Figure 3 D). Figure 3E reports the analytical parameters and linear range of MSA-ddPCR. In the range of 0.01% to 50% VAF, there is a strong linear correlation between the MSA-ddPCR detection concentration (Lg) and TP53R249S VAF (Lg). The fitting equation is y=0.7080x+3.181, and R2 is 0.9862. MSA-ddPCR is able to detect TP53R249S mutations with VAF as low as 0.01%.

[0063] like Figure 3 Optimization experiment and sensitivity evaluation are shown. (A) Analysis results of MSA-ddPCR at different annealing temperatures in FAM and VIC channels. Blue and green dots represent positive droplets, and gray dots represent negative droplets. The figures show the best results of three independent replicates. (B) Comparison of the optimization effects of betaine and DMSO. TP53R249S and TP53WT (TP53wild-type) plasmid DNA were used as templates for MSA-ddPCR. (C) Analysis results of plasmid DNA for detecting different VAFs in FAM and VIC channels. The concentration of TP53WT plasmid DNA was constant. (D) MSA-ddPCR results of 20 blank samples. LOB: limit of blank. (E) Sensitivity and regression analysis of MSA-ddPCR.

[0064] Example 4, Detection of mutations in clinical samples:

[0065] To verify the applicability of MSA-ddPCR in clinical samples, we analyzed 20 plasma samples (X1-X10, P1-P10) and 15 FFPE tissue samples (Q1-Q10, F1-F5) from Ningbo Second Hospital and Shanghai Cancer Center of Fudan University by MSA-ddPCR and amplicon high-throughput sequencing. The total amount of DNA extracted from plasma samples ranged from 50.05 to 104.7 ng / μL, and the total amount of DNA extracted from FFPE tissue samples ranged from 90.65 to 408.15 ng / μL. The results of MSA-ddPCR and amplicon high-throughput sequencing are shown in Figure 4 A. Kappa test results showed that amplicon high-throughput sequencing and MSA-ddPCR had good consistency in the ability to qualitatively analyze SNVs (Kappa = 0.884, P < 0.001). The negative and positive test results of the 33 samples by these two methods were consistent, with a consistency of 94.286% ( Figure 4B). Among these samples, one plasma sample (P10) and one FFPE tissue sample (Q9) were negative by amplicon high-throughput sequencing (VAF: 0%) but positive by MSA-ddPCR (VAF: 0.069% and 24.347%, respectively). Because the MSA-ddPCR results of these two samples were 0.663 copies / μL (P10) and 3.037 copies / μL (Q9), the reason for the inconsistent results may be that the copy numbers of mutant DNA in these two samples were too low to reach the LOD of the amplicon high-throughput sequencing method. The VAFs results of clinical samples obtained by amplicon high-throughput sequencing and MSA-ddPCR showed a moderate level of ICC correlation coefficient (ICC = 0.743; 95% CI (95% confidence interval) [0.548; 0.862]) ( Figure 4 C). Figure 4 There are two outliers in C (Q9, Q10). The VAFs detected by amplicon high-throughput sequencing and MSA-ddPCR for these two samples are very different (0% VS 24.347%, 69.455% VS 37.197%). On the one hand, it may be that the actual copy number of mutant DNA in these samples (3.037 copies / μL for Q9 and 5.106 copies / μL for Q10) affects the detection performance of amplicon high-throughput sequencing. On the other hand, it may be that the quality of DNA in the two FFPE tissue samples or certain amplification inhibition components contained in the samples affect the normal counting process of the two detection methods. In addition, Figure 4 The ROC curve shown in D shows that when the high-throughput sequencing method of amplified fragments (gold standard method) is used as a reference, the area under the curve (AUC) is 0.941, which also reflects that the two methods have good consistency in the ability to analyze SNVs.

[0066] like Figure 4 As shown, (A) Summary of the test results of MSA-ddPCR and amplicon high-throughput sequencing in plasma samples and FFPE (formalin-fixed paraffin-embedded) tissue samples. VAF: variant allele frequency. (B) Summary table of negative-positive results. (C) Correlation analysis of the test results of MSA-ddPCR and amplicon high-throughput sequencing in 35 samples. ICC=0.743, 95%CI[0.548-0.862]. ICC: intraclass correlation coefficient, 95%CI: 95% confidence interval. (D) ROC curve. When amplicon high-throughput sequencing was used as a reference, the AUC was 0.941. ROC curve: receiver operating characteristic curve, AUC: area under the curve. (E) Comparison of VAFs in FFPE tissue samples and plasma samples.

[0067] The present invention is a new method based on combining the amplification-blocking mutation system and digital droplet nucleic acid amplification technology: mutation-selective amplification droplet digital PCR (MSA-ddPCR). This method can perform highly sensitive quantitative analysis of SNVs, and its analysis results have low background values. Experimental results using TP53R249S plasmid as a template showed that MSA-ddPCR has high sensitivity and specificity and can be used as a reliable tool for the detection of clinical hotspot mutations.

[0068] In the primer and probe design stage, the present invention takes many measures to improve the accuracy and amplification efficiency of MSA-ddPCR. According to the amplification principle of MSA-ddPCR ( Figure 2 A), the number of long primers (L-Primer M1 and L-Primer W1) in the reaction system should be reduced. In MSA-ddPCR, the short primers (Primer 2, Primer3 and Primer 3) involved in the subsequent extension and fluorescence detection part should dominate. Therefore, the concentration ratio of long primers and short primers should be adjusted according to specific conditions. It has been verified that the optimal concentration of long primers in this study is 1 / 10 of that of short primers. In order to improve the ability of long primers to distinguish single-base differences in DNA templates and reduce the occurrence of non-specific signals, the present invention has taken the following measures: 1. Optimize the position and type of unpaired bases: We selected the penultimate base at the 3' end and designed an AG base mismatch, such as Figure 1As shown in B; 2. Combined with digital droplet generation technology: This technology can reduce the number of DNA molecules in each reaction microchamber to ≤1. Digital technology can also reduce the interference of impurities in the reaction system. In the amplification system, since the annealing temperature of the long primers used in the MSA-ddPCR of the present invention is relatively high, the present invention uses a probe with MGB, which improves the fluorescence reporting efficiency of the probe in the system and improves the accuracy of MSA-ddPCR. The MGB (small groove adhesive) at the 3' end of the probe can match the small groove of the DNA helix, thereby improving the accuracy and stability of hybridization by stabilizing the DNA double helix structure. After optimization experiments, we determined that the optimal annealing temperature of MSA-ddPCR is 68°C. Betaine was also identified as a nucleic acid amplification improver suitable for MSA-ddPCR. Using the optimized scheme, the present invention found that MSA-ddPCR can accurately quantify the TP53R249S mutation frequency as low as 0.01% in TP53WT plasmid DNA. Compared with other existing SNVs detection methods, the LOD of the method developed by the present invention in mutation detection is satisfactory (Table 1). In the application of clinical samples, the ability of MSA-ddPCR to detect mutant DNA is similar to or even better than that of amplicon high-throughput sequencing methods, which means that MSA-ddPCR can detect lower copy numbers in clinical samples. In addition, MSA-ddPCR can not only calculate the absolute copy number of wild-type DNA and mutant DNA in one reaction, but also is faster and less expensive (4 hours, US$30 / time) compared with high-throughput sequencing (7 days, US$100 / time). Currently, most available mutation detection protocols focus on their capabilities in plasma samples. However, in addition to plasma samples, the MSA-ddPCR developed in the present invention can also be used for low-quality DNA extracted from FFPE tissues. It is worth noting that in the study of the present invention, the VAFs of FFPE tissue samples were higher than those of plasma samples ( Figure 4 E). Therefore, in order to ensure the accuracy of mutation detection in practical applications, in addition to free cell DNA in plasma samples, testing FFPE tissue samples is also an alternative method.

[0069] Table 1. Comparison of LODs of currently reported SNVs detection methods.

[0070] serial number method LOD 1 Droplet digital PCR 0.1-1% 2 Hairpin Competition Amplification 0.01-0.1% 3 pTERT mutation analysis 0.27-0.42% 4 Trec-AMC-EXPAR 0.1% 5 Specific PCR combined with CRISPR / Cas12a 0.1% 6 Taqman-MGB nanoPCR 0.95% 8 Mutation-Specific ddPCR 0.05-0.06% 9 The EuroClonality-NGSDNA Capture assay 4% 10 MSA-ddPCR 0.01%

[0071] LOD: limit of detection.

[0072] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.

Claims

1. A method for detecting single nucleotide variations in tumor and plasma samples, characterized in that: The steps include: Step 1, sample preparation; Step 2, mixture preparation; Step 3, droplet generation; Step 4, performing a completely independent PCR amplification reaction on each droplet, wherein the PCR amplification reaction adopts a mutation selection amplification droplet digital PCR method that combines an amplification blocking mutation system with a digital droplet nucleic acid amplification technology; Step 5: Fluorescence detection: Extension phase: The long wild-type primer can bind to all DNA containing the TP53WT site and successfully extend. When the long mutant primer binds to the TP53WT template, the extension reaction is blocked due to the base mismatch at the 3' end of the long mutant primer. On the contrary, when the long mutant primer binds to the mutant template, it will successfully extend forward in the extension phase. The double-stranded DNA containing the extra fragment at the 5' end of the long mutant primer interacts with the primer and the probe, and then emits a corresponding fluorescent signal. Fluorescence detection stage: by combining with mutant probes or wild-type probes, the fluorescence signal of double-stranded DNA generated during primer binding can be detected; the droplets containing wild-type DNA can detect fluorescence signals in the VIC channel, the droplets containing mutant DNA can detect fluorescence signals in the FAM channel, and the droplets without target DNA molecules are negative droplets. The analysis instrument automatically collects the fluorescence signals emitted from different channels in all droplets and divides them into different clusters; Step 6, data analysis: Calculate the copy number of wild-type genes and mutant genes in each sample based on Poisson distribution, determine the frequency of variant alleles, and finally generate a clinical test report.

2. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 1, characterized in that: The method of mutation selection amplification droplet digital PCR described in step 4 comprises the following steps: Step a, design primers and probes: The primers include: a long primer for identifying mutant and wild-type fragments, and a short primer involved in subsequent extension and fluorescence detection; the long primers are L-Primer M1 and L-Primer W1, and the short primers are Primer2, Primer3 and Primer4; the probe is a probe with MGB, and the small groove adhesive MGB at the 3' end of the probe can match the small groove of the DNA helix; optimize the position and type of unpaired bases: select the second to last base at the 3' end, and design the AG base mismatch; Step b, combined with digital droplet generation technology: this technology can reduce the number of DNA molecules in each reaction microchamber to ≤1; the primer probe and sample are amplified in the MSA-ddPCR amplification system.

3. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 2, characterized in that: The method of mutation selection amplification droplet digital PCR described in step 4 comprises the following steps: Step a, design primers and probes: The primers include: a long primer for identifying mutant and wild-type fragments, and a short primer involved in subsequent extension and fluorescence detection; the long primers are L-Primer M1 and L-Primer W1, and the short primers are Primer2, Primer3 and Primer4; The probe is a probe with MGB, and the minor groove binder MGB at the 3' end of the probe can match the minor groove of the DNA helix; Optimize the position and type of mismatched bases: select the second to last base at the 3' end and design an AG base mismatch; The sequence of L-Primer W1 is: 5' GACGCCAGAATTGTCCGGTCGACGTCACGCCTGGCCCCAGCTGCTCACCATCGCT 3' SEQ ID No: 01; The sequence of L-Primer M1 is: 5′; GACGCCAGAATTGTCCGGTTGCCGACAGCCTGGCAGATGATGGTGAGGATGGGAC 3'SEQ ID No: 02; The sequence of Primer2 is: 5'GACGCCAGAATTGTCCGGT3' SEQ ID No: 03; The sequence of Primer3 is: 5'CTTGCCACAGGTCTCCCCAA3' SEQ ID No: 04; The sequence of Primer4 is: 5'TGGCCATCTACAAGCAGTCA3' SEQ ID No: 05; The sequence of the Wild Probe is: 5'VIC-CGACGTCACGCCTGGC-MGB 3' SEQ ID No: 06; The sequence of Mutant Probe is: 5'6-FAM-TGCCGACAGCCTGGCA-MGB 3'SEQ ID No:

07.

4. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 2, characterized in that: In the step b, the nucleic acid amplification improver is betaine.

5. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 2, characterized in that: In step b, the optimal concentration of the long primer is 1 / 10 of that of the short primer.

6. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 2, characterized in that: The reaction system of the MSA-ddPCR amplification system in step b includes: the total volume of MSA-ddPCR is 14 μL, including 7 μL of Premix Ex Taq TM (Probe qPCR), 0.7 μL L-Primer-W1 (1 μM), 0.7 μL L-Primer-M1 (1 μM), 0.7 μL Primer 2 (10 μM), 0.7 μL Primer3 (10 μM), 0.7 μL Primer4 (10 μM), 0.7 μL WildProbe (10 μM), 0.7 μL Mutant Probe (10μM), 1.4μL template DNA and 0.7μL DEPC H2O.

7. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 2, characterized in that: The amplification steps of the MSA-ddPCR amplification system in step b are as follows: pre-denaturation at 95°C for 30 seconds, followed by 37 cycles of denaturation at 95°C for 5 seconds, annealing and extension at 68°C for 30 seconds, and then cooling to 50°C for 15 seconds.

8. A method for detecting single nucleotide variations in tumor and plasma samples according to claim 1, characterized in that: The samples tested include: free cell DNA in plasma samples or FFPE tissue samples.